162 related articles for article (PubMed ID: 37894448)
1. Immunogenic Biomarkers HMGB1 and sRAGE Are Potential Diagnostic Tools for Ovarian Malignancies.
Schröder L; Rupp ABA; Gihr KME; Kobilay M; Domroese CM; Mallmann MR; Holdenrieder S
Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894448
[TBL] [Abstract][Full Text] [Related]
2. Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy.
Stoetzer OJ; Fersching DM; Salat C; Steinkohl O; Gabka CJ; Hamann U; Braun M; Feller AM; Heinemann V; Siegele B; Nagel D; Holdenrieder S
Tumour Biol; 2013 Feb; 34(1):81-90. PubMed ID: 22983919
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of high mobility group box-1 protein (HMGB1) and soluble receptors of advanced glycation end-products (RAGE) in depressed patients treated with electroconvulsive therapy.
Abe H; Okada-Tsuchioka M; Kajitani N; Omori W; Itagaki K; Shibasaki C; Boku S; Matsuhisa T; Takebayashi M
Neuropsychopharmacol Rep; 2023 Sep; 43(3):359-364. PubMed ID: 37337402
[TBL] [Abstract][Full Text] [Related]
4. Relevance of Circulating Nucleosomes, HMGB1 and sRAGE for Prostate Cancer Diagnosis.
Garrido MM; Ribeiro RM; Krüger K; Pinheiro LC; Guimarães JT; Holdenrieder S
In Vivo; 2021; 35(4):2207-2212. PubMed ID: 34182498
[TBL] [Abstract][Full Text] [Related]
5. The association between plasma HMGB1 and sRAGE and clinical outcome in intracerebral hemorrhage.
Lei C; Geng J; Zhong L
J Neuroimmunol; 2020 Aug; 345():577266. PubMed ID: 32470565
[TBL] [Abstract][Full Text] [Related]
6. High-mobility group box-1 and receptor for advanced glycation end products in preterm infants with brain injury.
Lu HY; Ma JL; Shan JY; Zhang J; Wang QX; Zhang Q
World J Pediatr; 2017 Jun; 13(3):228-235. PubMed ID: 27995540
[TBL] [Abstract][Full Text] [Related]
7. Circulating levels of soluble receptor for advanced glycation end products and ligands of the receptor for advanced glycation end products in patients with acute liver failure.
Basta G; Del Turco S; Navarra T; Lee WM;
Liver Transpl; 2015 Jun; 21(6):847-54. PubMed ID: 25825217
[TBL] [Abstract][Full Text] [Related]
8. [The Value of Serum HMGB1 and sRAGE in the Diagnosis, Efficacy Monitoring and Prognosis of Newly Diagnosed Multiple Myeloma].
Wang J; Zeng AM; Liang SF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Apr; 30(2):493-500. PubMed ID: 35395985
[TBL] [Abstract][Full Text] [Related]
9. Elevated HMGB1 and sRAGE levels in cerebrospinal fluid of aneurysmal subarachnoid hemorrhage patients.
Chu XH; Hu HY; Godje ISG; Zhu LJ; Zhu JB; Feng YL; Wang H; Zhang YB; Huang J; Sun XG
J Stroke Cerebrovasc Dis; 2023 May; 32(5):107061. PubMed ID: 36871437
[TBL] [Abstract][Full Text] [Related]
10. Effects of AGEs, sRAGE and HMGB1 on Clinical Outcomes in Multiple Myeloma.
Geduk A; Oztas B; Eryılmaz BH; Demirsoy ET; Menguc MU; Unal S; Mersin S; Polat MG; Aygun K; Yenihayat EM; Albayrak H; Erol HA; Balcı S; Mehtap O; Tarkun P; Hacihanefioglu A
Indian J Hematol Blood Transfus; 2023 Apr; 39(2):220-227. PubMed ID: 37006982
[TBL] [Abstract][Full Text] [Related]
11. Circulating nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advanced pancreatic cancer undergoing chemotherapy.
Wittwer C; Boeck S; Heinemann V; Haas M; Stieber P; Nagel D; Holdenrieder S
Int J Cancer; 2013 Dec; 133(11):2619-30. PubMed ID: 23729200
[TBL] [Abstract][Full Text] [Related]
12. The presence of high mobility group box-1 and soluble receptor for advanced glycation end-products in juvenile idiopathic arthritis and juvenile systemic lupus erythematosus.
Bobek D; Grčević D; Kovačić N; Lukić IK; Jelušić M
Pediatr Rheumatol Online J; 2014; 12():50. PubMed ID: 25516724
[TBL] [Abstract][Full Text] [Related]
13. Increased levels of soluble receptor for advanced glycation end products (sRAGE) and high mobility group box 1 (HMGB1) are associated with death in patients with acute respiratory distress syndrome.
Nakamura T; Sato E; Fujiwara N; Kawagoe Y; Maeda S; Yamagishi S
Clin Biochem; 2011 Jun; 44(8-9):601-4. PubMed ID: 21211520
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic Utility and Tendency of Bronchial and Serum Soluble Receptor for Advanced Glycation EndProducts (sRAGE) in Lung Cancer.
Kim T; Kim SJ; Choi H; Shin TR; Sim YS
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345156
[TBL] [Abstract][Full Text] [Related]
15. Reduced soluble RAGE is associated with disease severity of axonal Guillain-Barré syndrome.
Zhang DQ; Wang R; Li T; Zhou JP; Chang GQ; Zhao N; Yang LN; Zhai H; Yang L
Sci Rep; 2016 Feb; 6():21890. PubMed ID: 26902096
[TBL] [Abstract][Full Text] [Related]
16. Alarmins and Related Molecules in Elective Surgery.
Strohalmová S; Levová K; Kuběna AA; Hoskovec D; Krška Z; Zima T; Kalousová M
Folia Biol (Praha); 2023; 69(2):50-58. PubMed ID: 38063001
[TBL] [Abstract][Full Text] [Related]
17. Soluble receptor for advanced glycation end-products and progression of airway disease.
Iwamoto H; Gao J; Pulkkinen V; Toljamo T; Nieminen P; Mazur W
BMC Pulm Med; 2014 Apr; 14():68. PubMed ID: 24758342
[TBL] [Abstract][Full Text] [Related]
18. Plasma levels of high-mobility group box 1 and soluble receptor for advanced glycation end products in primary antiphospholipid antibody syndrome patients.
Tang KT; Hsieh TY; Chao YH; Lin MX; Chen YH; Chen DY; Lin CC
PLoS One; 2017; 12(5):e0178404. PubMed ID: 28558055
[TBL] [Abstract][Full Text] [Related]
19. sRAGE alleviates neutrophilic asthma by blocking HMGB1/RAGE signalling in airway dendritic cells.
Zhang F; Su X; Huang G; Xin XF; Cao EH; Shi Y; Song Y
Sci Rep; 2017 Oct; 7(1):14268. PubMed ID: 29079726
[TBL] [Abstract][Full Text] [Related]
20. Sympathoadrenergic suppression improves heart function by upregulating the ratio of sRAGE/RAGE in hypertension with metabolic syndrome.
Selejan SR; Linz D; Tatu AM; Hohl M; Speer T; Ewen S; Mahfoud F; Kindermann I; Zamyatkin O; Kazakov A; Laufs U; Böhm M
J Mol Cell Cardiol; 2018 Sep; 122():34-46. PubMed ID: 30096408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
